NL8101191A - Oxytocine derivaat; farmaceutisch preparaat; werkwijze voor het tegengaan van spiercontracties van de uterus. - Google Patents

Oxytocine derivaat; farmaceutisch preparaat; werkwijze voor het tegengaan van spiercontracties van de uterus. Download PDF

Info

Publication number: NL8101191A
Authority: NL; Netherlands
Prior art keywords: oxytocin; uterus; derivative; pharmaceutical composition; uterine
Prior art date: 1980-03-24

Application number

NL8101191A

Other languages

English (en)

Dutch (nl)

Original Assignee

Ferring Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-03-24

Filing date

1981-03-11

Publication date

1981-10-16

1981-03-11 Application filed by Ferring Ab filed Critical Ferring Ab

1981-10-16 Publication of NL8101191A publication Critical patent/NL8101191A/nl

Links

XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims description 50
210000004291 uterus Anatomy 0.000 title claims description 14
238000000034 method Methods 0.000 title claims description 8
210000003205 muscle Anatomy 0.000 title description 3
239000000825 pharmaceutical preparation Substances 0.000 title description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
-1 3-mercaptopropionyl group Chemical group 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
230000004118 muscle contraction Effects 0.000 claims description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
229930195725 Mannitol Natural products 0.000 claims description 3
239000000594 mannitol Substances 0.000 claims description 3
235000010355 mannitol Nutrition 0.000 claims description 3
239000002504 physiological saline solution Substances 0.000 claims description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
108010050848 glycylleucine Proteins 0.000 claims description 2
229960001723 oxytocin Drugs 0.000 description 39
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
101800000989 Oxytocin Proteins 0.000 description 23
102400000050 Oxytocin Human genes 0.000 description 23
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 23
230000000694 effects Effects 0.000 description 20
230000008602 contraction Effects 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000000556 agonist Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 6
108010004977 Vasopressins Proteins 0.000 description 6
102000002852 Vasopressins Human genes 0.000 description 6
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
230000002269 spontaneous effect Effects 0.000 description 6
229960003726 vasopressin Drugs 0.000 description 6
229920005654 Sephadex Polymers 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
206010013935 Dysmenorrhoea Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
238000012404 In vitro experiment Methods 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 2
NDBNSZKHDMXOJE-UHFFFAOYSA-N 3-benzylsulfanylpropanoic acid Chemical compound OC(=O)CCSCC1=CC=CC=C1 NDBNSZKHDMXOJE-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010048179 Lypressin Proteins 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000003708 ampul Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229960003837 lypressin Drugs 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000002632 myometrial effect Effects 0.000 description 2
210000000754 myometrium Anatomy 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000036407 pain Effects 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000009291 secondary effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000003191 uterotonic effect Effects 0.000 description 2
DJUKMSKWRAHKNJ-KQOKFJBASA-N (2s)-1-[(4r,7s,10s,16s,19r)-19-acetamido-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-methoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(C)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 DJUKMSKWRAHKNJ-KQOKFJBASA-N 0.000 description 1
102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
108700022152 N-acetyl-2-O-methyl-Tyr- oxytocin Proteins 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8101191A 1980-03-24 1981-03-11 Oxytocine derivaat; farmaceutisch preparaat; werkwijze voor het tegengaan van spiercontracties van de uterus. NL8101191A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE8002222		1980-03-24
SE8002222A SE430885B (sv)	1980-03-24	1980-03-24	Oxytocin-derivat

Publications (1)

Publication Number	Publication Date
NL8101191A true NL8101191A (nl)	1981-10-16

Family

ID=20340577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8101191A NL8101191A (nl)	1980-03-24	1981-03-11	Oxytocine derivaat; farmaceutisch preparaat; werkwijze voor het tegengaan van spiercontracties van de uterus.

Country Status (10)

Country	Link
US (1)	US4402942A (it)
JP (1)	JPS56150050A (it)
BE (1)	BE887970A (it)
CH (1)	CH646139A5 (it)
DE (1)	DE3108323C2 (it)
FR (1)	FR2482093A1 (it)
GB (1)	GB2074582B (it)
IT (1)	IT1136574B (it)
NL (1)	NL8101191A (it)
SE (1)	SE430885B (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7722733B2 (en)	2004-03-29	2010-05-25	Baxter International Inc.	Method for sterile connection of tubing

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8207277L (sv) *	1982-12-21	1984-06-22	Ferring Ab	Vasotocin-derivat
DE10075020I2 (de) *	1982-12-21	2003-01-09	Ferring Ab	Vasotocinderivate
US4483794A (en) *	1983-05-10	1984-11-20	Ceskoslovenska Akademie Ved	Analogs of neurohypophysial hormones
US4624943A (en) *	1985-03-20	1986-11-25	Smithkline Beckman Corporation	Aromatic basic-tailed vasopressin antagonists
US5225528A (en) *	1990-02-27	1993-07-06	Merck & Co., Inc.	Cyclic hexapeptide oxytocin antagonists
DE4042008A1 (de) *	1990-12-22	1992-06-25	Schering Ag	Vasopressin-derivate
US5830848A (en) *	1992-10-09	1998-11-03	The Regents Of The University Of California	Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
RU2125062C1 (ru) *	1997-04-10	1999-01-20	Государственный научный центр вирусологии и биотехнологии "Вектор"	Защищенные производные окситоцина
US6680415B1 (en) *	1999-11-22	2004-01-20	Dow Global Technologies Inc.	Oxyhalogenation process using catalyst having porous rare earth halide support
US6797845B1 (en)	1999-11-22	2004-09-28	Dow Global Technologies Inc.	Process for vinyl chloride manufacture from ethane and ethylene with immediate HCl recovery from reactor effluent
US6933417B1 (en)	1999-11-22	2005-08-23	Dow Global Technologies Inc.	Process for vinyl chloride manufacture from ethane and ethylene with partial CHl recovery from reactor effluent
US6909024B1 (en)	1999-11-22	2005-06-21	The Dow Chemical Company	Process for the conversion of ethylene to vinyl chloride and novel catalyst compositions useful for such process
SE0100684D0 (sv) *	2001-02-28	2001-02-28	Kerstin Uvnaes Moberg	New subject-matter
CA2448500C (en) *	2001-05-23	2009-11-17	Dow Global Technologies Inc.	Oxidative halogenation and optional dehydrogenation of c3+ hydrocarbons
US20040152929A1 (en) *	2002-05-08	2004-08-05	Clarke William D	Process for vinyl chloride manufacture from ethane and ethylene with air feed and alternative hcl processing methods
TWI463990B (zh) *	2009-09-21	2014-12-11	Ferring Bv	催產素受體促進劑
MX392636B (es)	2014-10-31	2025-03-24	Glaxosmithkline Ip Dev Ltd	Formulacion en polvo.
CA3009576A1 (en)	2016-01-04	2017-07-13	Merck Serono S.A.	L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
UA127283C2 (uk)	2016-07-21	2023-07-12	Обсева С.А.	Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню
WO2020137880A1 (ja) *	2018-12-27	2020-07-02	国立大学法人北海道大学	オキシトシン誘導体及びその使用
US20220323410A1 (en)	2019-09-03	2022-10-13	ObsEva S.A.	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en)	2020-02-10	2021-08-19	ObsEva S.A.	Biomarkers for oxytocin receptor antagonist therapy
JP2023550555A (ja)	2020-11-16	2023-12-01	ゾーマ（ユーエス）エルエルシー	早期分娩の治療または予防のための組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1463865A (fr) *	1964-07-27	1966-07-22	Ceskoslovenska Akademie Ved	Procédé pour la préparation des dérivés cycliques de peptides ainsi que les produits conformes à ceux obtenus par le présent procédé ou procédé similaire
CS194980B1 (en) *	1976-07-16	1979-12-31	Joseph H Cort	Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle

1980
- 1980-03-24 SE SE8002222A patent/SE430885B/sv not_active IP Right Cessation
1981
- 1981-02-27 US US06/238,715 patent/US4402942A/en not_active Expired - Fee Related
- 1981-03-03 CH CH140781A patent/CH646139A5/de not_active IP Right Cessation
- 1981-03-04 GB GB8106843A patent/GB2074582B/en not_active Expired
- 1981-03-05 DE DE3108323A patent/DE3108323C2/de not_active Expired
- 1981-03-11 NL NL8101191A patent/NL8101191A/nl not_active Application Discontinuation
- 1981-03-16 BE BE0/204141A patent/BE887970A/fr not_active IP Right Cessation
- 1981-03-23 JP JP4227581A patent/JPS56150050A/ja active Pending
- 1981-03-23 FR FR8105751A patent/FR2482093A1/fr active Granted
- 1981-03-24 IT IT20684/81A patent/IT1136574B/it active

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7722733B2 (en)	2004-03-29	2010-05-25	Baxter International Inc.	Method for sterile connection of tubing
US8162021B2 (en)	2004-03-29	2012-04-24	Baxter International	Apparatus for sterile connection of tubing

Also Published As

Publication number	Publication date
DE3108323C2 (de)	1983-11-24
IT1136574B (it)	1986-09-03
FR2482093A1 (fr)	1981-11-13
DE3108323A1 (de)	1981-12-24
IT8120684A0 (it)	1981-03-24
SE8002222L (sv)	1981-09-25
FR2482093B1 (it)	1984-11-09
US4402942A (en)	1983-09-06
SE430885B (sv)	1983-12-19
BE887970A (fr)	1981-07-16
GB2074582A (en)	1981-11-04
GB2074582B (en)	1983-07-06
JPS56150050A (en)	1981-11-20
CH646139A5 (de)	1984-11-15

Legal Events

Date	Code	Title
1981-10-16	A1A	A request for search or an international-type search has been filed
1982-11-01	BB	A search report has been drawn up
1984-01-02	BC	A request for examination has been filed
1985-01-01	A85	Still pending on 85-01-01
1988-11-01	BV	The patent application has lapsed

Publication	Publication Date	Title
NL8101191A (nl)	1981-10-16	Oxytocine derivaat; farmaceutisch preparaat; werkwijze voor het tegengaan van spiercontracties van de uterus.
US6569845B1 (en)	2003-05-27	Neovascularization inhibitor containing dienogest as the active ingredient
KR20010013712A (ko)	2001-02-26	수용성 케토프로펜 염을 함유하는 약학적 제제 및 그의 용도
EP2552470B1 (en)	2016-09-07	Peptides for promoting angiogenesis and an use thereof
JP7126270B2 (ja)	2022-08-26	Ｎｐｒａアゴニスト、組成物およびその使用
EP0112809A1 (en)	1984-07-04	Vasotocin derivatives
KR0124817B1 (ko)	1997-11-25	4-퀴놀린 카복실산 유도체를 포함하는 피부 및 점막-상피성 질환 치료용 약제학적 조성물
KR20180052642A (ko)	2018-05-18	장시간 작용형 아드레노메둘린 유도체
JPH06234637A (ja)	1994-08-23	腫瘍壊死因子アルファを阻害するためのレフルノミドの使用
Melin et al.	1981	Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity
CA2066155A1 (en)	1992-02-03	Antiviral agent for human immunodeficiency virus
EP0661053A1 (en)	1995-07-05	Use of tocopherol ascorbic adic phosphates for hemorrhoidal diseases
EP1908779A1 (en)	2008-04-09	Thymosin beta 4 derivatives and use thereof
KR100244624B1 (ko)	2000-02-15	황체 형성 호르몬 방출 호르몬(lhrh) 길항제 및 이를 함유하는 약제학적 조성물
CA2072253A1 (en)	1991-07-10	Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
EP0005015B1 (en)	1986-10-29	Use of a xanthine derivate in the manufacture of a medicament
US9249185B2 (en)	2016-02-02	Peptides for promoting angiogenesis and an use thereof
HU202754B (en)	1991-04-29	Process for producing flavoxate derivatives and pharmaceutical compositions containing them as active components
Bache et al.	1988	Effects of atrial natriuretic peptide in the canine coronary circulation.
EP0650723A2 (en)	1995-05-03	Novel pharmaceutical use of forskolin derivatives
Su	1992	Cell protection mechanism of antishock action of anisodamine
EP0005074A1 (en)	1979-10-31	A material and composition for reducing blood pressure
US6306845B1 (en)	2001-10-23	Method for treating demyelinating disease
IE912378A1 (en)	1992-01-15	Derivatives of pituitary posterior lobe hormones
JP2002502399A (ja)	2002-01-22	プライマー化合物による抗癌剤の固形癌への増強された送達